3 results
Currently, no robust clinical data are available comparing interventional ablation strategies in the setting of persistent AF with enlarged Atrium > 4 cm and longstanding persistent AF, which reflects a difficult to treat patient-subgroup.…
Therapy:The investigational product, ACP-196, will be supplied as hardgelatin capsules for oral administration.Commercially available ibrutinib (IMBRUVICA®) will be used asthe reference therapy.Objectives: Primary Objective:To assess whether ACP-196…
Primary: To describe safety and tolerability during longer-term administration of AR101 and follow-up observation after the last dose of AR101.Secondary: - To assess the level of desensitization achievable through extended maintenance dosing of…